If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
200
results.
Updated on
14/09/2026 [06:52:00]
Results 25 to 50 of 200
Absstract of: US20260263267A1
Devices, methods, and kits for ocular drug delivery are described herein. In some embodiments, a method includes inserting a distal end portion of a puncture member into an eye to define a delivery passageway within the eye. The delivery passageway extends through ha sclera of the eye and a choroid of the eye. The delivery passageway is less than about 1.5 mm. The method further includes conveying a substance into a subretinal space within the eye via the distal end portion of the puncture member.
Absstract of: US20260263362A1
0000 The present invention relates to novel ecto-liposome fusion nanoparticles, and more specifically, provides novel stem cell-derived ecto-liposome fusion nanoparticles exhibiting superior targeting capability to a tumor site compared to conventional drug delivery carriers having targeting capability.
Absstract of: US20260263373A1
Nanoparticle compositions and methods inhibiting amyloid beta (Aβ) fibrilization in a subject in need thereof using nanoparticles to target fibril β-amyloid (fAβ)-specific scavenger receptors. Also provided is a method of using nanoparticle compositions to treat Alzheimer's disease (AD) and similar amyloidopathies.
Absstract of: US20260265348A1
Described is a (first) anti-HSV antibody or an antigen-binding fragment thereof binding to the glycoprotein B (gB) of HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said antibody or antigen-binding fragment has a low dissociation rate kdis of at most 5.0×10−4 s−1, preferably at most 1.0×10−4 s−1, at most 5.0×10−5 s−1, and most preferably at most 2.9×10−5 s−1. Moreover, described is a combination of (A) said (first) anti-HSV antibody or an antigen-binding fragment thereof; and (B) a second anti-HSV antibody or an antigen-binding fragment thereof recognizing/binding to the glycoprotein B (gB) of the HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Further, described is a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or the antigen-binding fragment thereof or the combination of said antibodies and at least one pharmaceutically acceptable excipient. Further, described is an anti-HSV antibody or the antigen-binding fragment t
Absstract of: US20260263618A1
0000 Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Absstract of: US20260263510A1
0000 A method of treating a COVID-19 infection including administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The particles of the composition are monodisperse, and spherical, and have an average diameter of 70-100 nanometers (nm).
Absstract of: US20260263375A1
The disclosure provides lipid nanoparticle compositions comprising nucleic acids encoding RSV antigenic polypeptides. The present disclosure also provides novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.
Absstract of: US20260263376A1
A nanoparticle for encapsulation of one or more active pharmaceutical ingredient, said nanoparticle comprising an amphiphilic block copolymer, wherein said amphiphilic block copolymer comprises: i. a hydrophobic polymer block comprising structural units of trimethylene carbonate; and ii. a hydrophilic polymer block comprising structural units of one or more alkylene glycols. A drug delivery vector comprising one or more active pharmaceutical ingredients encapsulated within said nanoparticle. A process for preparing said nanoparticle, the process comprising: i. dissolving said amphiphilic block copolymer in an oligomeric alkylene glycol solution to prepare an alkylene glycol-polymer solution; and ii. hydrating said alkylene glycol-polymer solution by addition of water, an aqueous solution or an aqueous buffer to prepare said nanoparticle. A process for preparing said drug delivery vector by encapsulating one or more active pharmaceutical ingredients within a nanoparticle, wherein said process comprises: i. co-dissolving said amphiphilic block copolymer and said one or more active pharmaceutical ingredients in an oligomeric alkylene glycol solution to prepare an alkylene glycol-polymer solution; and ii. hydrating said alkylene glycol-polymer solution by the addition of water, an aqueous solution or an aqueous buffer to prepare said drug delivery vector. Said drug delivery vector for use as a medicament, preferably for use in the treatment of cancer.
Absstract of: US20260263556A1
The present invention relates to a lipid nanoparticle comprising mRNA encoding FOXP3 and at least a second polypeptide, wherein said lipid nanoparticle comprises a moiety capable of specifically binding to a molecule expressed on a CD4+ T cell and wherein said mRNA is modified to have increased stability as compared to unmodified mRNA.
Absstract of: US20260263353A1
This invention relates to drug-device core-shell microneedle devices containing anti-diabetes and anti-obesity medications, and transdermal delivery of said medications. The microneedle drug-device system comprises: (a) a two-dimensional array of conical bilayer containing an inner layer with the base diameter ranging from about 100 μm to about 500 μm and the height ranging from about 100 μm about 1200 μm capable of accommodating a known amount of anti-diabetes and/or anti-obesity medications, and a suitable, photostable chromophore or a fluorophore whose absorption and/or emission occurring in the range of 400-900 nm; (b) a larger outer layer that adheres to and encapsulates the inner layer, and protects the inner layer, and (c) a two-dimensional array of cylindrical ‘cap layer’ that aligns with and adheres to the basal surface of core shell bilayer and seals the bilayer to prevent leakage of said medication(s). The apical (i.e., sharp) ends of the conical bilayer array inserts into the skin and are programmed to allow the said medications to effuse out of the bilayer and into the skin in a controlled fashion and to be monitored by photodetection devices.
Absstract of: US20260263354A1
Disclosed herein are aspects of a microneedle array comprising a metal-organic framework (MOF)-vaccine biocomposite and methods for using the same. The microneedle array further comprises a dissolvable material that dissolved when inserted into the skin of a subject, thereby releasing the MOF-vaccine biocomposite. The MOF may be selected to dissolve in an acidic environment, thereby targeting the vaccine delivery to specific cellular compartments. Methods for making the MOF-vaccine biocomposite and the microneedle array also are disclosed.
Absstract of: US20260265349A1
The present disclosure relates to the field of nanobodies, therapeutic agents, compositions and methods for the prevention, amelioration and treatment of noroviral infections.
Absstract of: WO2026185898A1
The present disclosure relates to pharmaceutical coating compositions containing a combination of lipid-polymer hybrid nanoparticles and Sirolimus nanoparticles. Particularly the present invention provides for a sirolimus nanoparticle, wherein the sirolimus is a crystalline nanorod having a length in the range of 10 nm to 950 nm longitudinally. Also, the sirolimus nanorod containing coating composition performs better in terms of pharmaceutical agent retention, absorption in tissues and result in sustained and controlled release over a time.. The invention also describes methods to prepare nanoparticles and nanoparticle containing coating compositions. Specifically, the invention is related to pharmaceutical coating compositions for medical devices and pharmaceutical agent delivery.
Absstract of: WO2026186913A1
The purpose of the present invention is to: solve problems in various medicines including a nucleic acid medicine, such as instability in a living body, non-specific in-vivo distribution, and cytotoxicity and immunostimulatory properties caused by conventional cationic lipids; and safely and selectively deliver a medicine to a target cell or a target tissue. The present invention provides: a non-cationic lipid comprising a neutral phospholipid and/or an anionic phospholipid and cholesterol or a derivative thereof; a non-cationic lipid obtained by modifying said lipid with a ligand; and non-cationic lipid nanoparticles formed by the self-assembly of said non-cationic lipids. An aptamer is particularly preferable as the ligand, and a drug delivery system having both low toxicity and high target directivity is achieved by sealing a medicine, such as a nucleic acid medicine, in the nanoparticle.
Absstract of: WO2026187895A2
The processes and buffer compositions described in the inventions provide a significant improvement in the stability of mRNA within lipid nanoparticles. By controlling adduct formation and mRNA degradation, these compositions enhance the efficacy and shelf-life of mRNA-based therapeutics.
Absstract of: WO2026187549A1
Nanoconjugates comprising myeloid-derived suppressor cells conjugated to nanoparticles optionally encapsulating therapeutic agents, nanoparticles comprising poly( lactic-co-glycolic acid), poly(lactide-co-glycolide)-b-poly(ethylene glycol ) methyl ether and poly(Lactide-co-glycolide)-poly(ethylene glycol) with dibenzocycolctyne, myeloid-derived suppressor cells comprising functional groups capable of forming a covalent bonds with nanoparticles, and methods of using the nanoconj ugates to treat inflammatory or autoimmune diseases or conditions including multiple sclerosis.
Absstract of: US20260263633A1
Disclosed are a mixed nano-lipid delivery system for mRNA, and a preparation method therefor and a use thereof. The delivery system is composed of an anionic and cationic mixed lipid, PEG2000-DSPE, a buffer system and mRNA; the anionic and cationic mixed lipid is composed of anionic nucleoside phospholipid TPS or CPS and cationic peptide lipid CLD or CLDA; and the buffer system is a PBS or Opti-MEM™ buffer system containing Ca2+ having a concentration 0.1 mM. The delivery system can efficiently deliver mRNA into cells and mice, and can realize long-time stable expression of proteins in vivo. In addition, an HPV E7 mRNA vaccine provided by the present disclosure can successfully activate humoral and cellular immunity in mice, reduce the mortality rate of HPV-related cervical cancer mice, and have good safety.
Absstract of: US20260263631A1
An object of the present invention is to provide a biocompatible carrier material capable of locally releasing particles.The present inventors have found that by using a non-gelling polymer formed by reversibly bonding a plurality of hydrophilic polymer units as a carrier material, it is possible to locally release particles to an affected part such as an ulcer surface, thereby enhancing gene transduction specificity and reducing off-target effects.
Absstract of: US20260263374A1
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns nanoparticles and/or aggregates of nanoparticles, a composition comprising said nanoparticles and/or aggregates of nanoparticles, and their use in the treatment of NP.
Absstract of: WO2026187181A1
The present invention relates to a mannan nanoparticle using chemically modified mannan and immunomodulatory uses thereof and, more specifically, to an immunomodulatory mannan nanoparticle comprising: a nanoparticle; a cationic polymer coating layer having an amine group formed on the surface of the nanoparticle; and chemically modified mannan bonded to the coating layer, and to an immunomodulatory composition comprising the nanoparticle as an active ingredient. The present invention also relates to a method for reprogramming fully differentiated M1 or M2 macrophages into M2 or M1 macrophages, the method comprising a step of treating and culturing the fully differentiated M1/M2 macrophages with the mannan nanoparticle.
Absstract of: WO2026183772A1
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules encoding gene editing machinery) for therapeutic or prophylactic purposes.
Absstract of: WO2026186988A1
The present invention relates to a cationic lipid, a method for preparing same, and a composition of nanoparticles for drug delivery comprising same. More specifically, the present invention relates to: a cationic lipid useful for drug delivery, which forms or is capable of forming a complex with an anionic drug due to a specific structure; a method for preparing the cationic lipid; a composition for drug delivery in which a drug is encapsulated in a nanoparticle structure formed by the cationic lipid and a polymer; and a method for preparing the composition.
Absstract of: WO2026185468A1
The invention provides compositions comprising recombinant targeting peptides that bind specifically to the cell wall of Cutibacterium acnes. The compositions find use in controlling, improving and/or treating microbial infections and skin conditions, for example acne.
Absstract of: US20260263379A1
Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advanc
Nº publicación: US20260263569A1 10/09/2026
Applicant:
THE UNIV OF CHICAGO [US]
The University of Chicago
Absstract of: US20260263569A1
This disclosure relates to lipid nanoparticle composition comprising polyamidoamine (PAMAM) dendrimer (G0-C14), cholesterol, polyethylene glycol 2000 (PEG), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol) (DSPE-PEG), dioleoylphospha-tidylethanolamine (DOPE), and PLPP3 mRNA encapsulated by the lipid nanoparticle, and methods for treating arterial disease, including, for example, atherosclerosis, peripheral artery disease, ischemic stroke, and stenosis.
BOPI
Electronic site
